Showing 1 - 6 results of 6 for search 'Leonardo Provenzano', query time: 0.03s Refine Results
  1. 1
    The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis

    The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrosp... by Leonardo Provenzano, Riccardo Lobefaro, Francesca Ligorio, Emma Zattarin, Luca Zambelli, Caterina Sposetti, Daniele Presti, Giulia Montelatici, Angela Ficchì, Antonia Martinetti, Alessio Arata, Marta Del Vecchio, Claudia Lauria Pantano, Barbara Formisano, Giulia Valeria Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri, Giovanni Fucà

    Published 2023-04-01
    Get full text
    Article
  2. 2
    Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade

    Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade by Akihito Kawazoe, Kohei Shitara, Sara Lonardi, Filippo Pietrantonio, Samuel J Klempner, Thierry André, Massimiliano Salati, Margherita Ambrosini, Giovanni Randon, Romain Cohen, Paolo Manca, Vincenzo Nasca, Joseph Chao, Leonardo Provenzano, Yu Aoki, Steven B Maron, Riccardo Cerantola, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Valerie Zhu, Darren Cowzer, Virginia Genovesi

    Published 2023-06-01
    Get full text
    Article
  3. 3
    Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients

    Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients by Arsela Prelaj, Arsela Prelaj, Edoardo Gregorio Galli, Edoardo Gregorio Galli, Edoardo Gregorio Galli, Vanja Miskovic, Mattia Pesenti, Giuseppe Viscardi, Giuseppe Viscardi, Benedetta Pedica, Laura Mazzeo, Laura Mazzeo, Laura Mazzeo, Achille Bottiglieri, Achille Bottiglieri, Leonardo Provenzano, Leonardo Provenzano, Andrea Spagnoletti, Andrea Spagnoletti, Roberto Marinacci, Alessandro De Toma, Claudia Proto, Roberto Ferrara, Marta Brambilla, Mario Occhipinti, Sara Manglaviti, Giulia Galli, Diego Signorelli, Diego Signorelli, Claudia Giani, Claudia Giani, Teresa Beninato, Teresa Beninato, Chiara Carlotta Pircher, Chiara Carlotta Pircher, Alessandro Rametta, Alessandro Rametta, Sokol Kosta, Michele Zanitti, Maria Rosa Di Mauro, Arturo Rinaldi, Settimio Di Gregorio, Martinetti Antonia, Marina Chiara Garassino, Marina Chiara Garassino, Filippo G. M. de Braud, Filippo G. M. de Braud, Marcello Restelli, Giuseppe Lo Russo, Monica Ganzinelli, Francesco Trovò, Alessandra Laura Giulia Pedrocchi

    Published 2023-01-01
    Get full text
    Article
  4. 4
    Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

    Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors by Emma Zattarin, Luigi Mariani, Alice Menichetti, Rita Leporati, Leonardo Provenzano, Francesca Ligorio, Giovanni Fucà, Riccardo Lobefaro, Luca Lalli, Andrea Vingiani, Federico Nichetti, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Chiara Corti, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Daniele Presti, Caterina Sposetti, Carlo Alberto Giorgi, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Daniele Generali, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri

    Published 2023-12-01
    Get full text
    Article
  5. 5
    PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1

    PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 by Filippo de Braud, Valter Torri, Giuseppe Lo Russo, Claudia Proto, Roberto Ferrara, Monica Ganzinelli, Marina Chiara Garassino, Giuseppe Viscardi, Giorgio Trinchieri, Mario Occhipinti, Rita Leporati, Marta Brambilla, Luca Agnelli, Silvia Brich, Francesco Sgambelluri, Roberta Mortarini, Andrea Anichini, Leonardo Provenzano, Daniele Lorenzini, Arsela Prelaj, James Dolezal, Teresa Beninato, Tiziana Triulzi, Alessandra Fabbri, Laura Mazzeo, Andrea Spagnoletti, Vanja Miskovic, Alessandra Laura Giulia Pedrocchi, Francesco Trovo', Sara Manglaviti, Claudia Giani, Paolo Ambrosini, Andrea Franza, John McCulloch, Tommaso Torelli, Giancarlo Pruneri

    Published 2023-06-01
    Get full text
    Article
  6. 6
    Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

    Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors by Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fucà, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri

    Published 2023-04-01
    Get full text
    Article

Search Tools: